Bifidobacterium regulates premature infant gut metabolites, reducing serum inflammatory factors: a randomised controlled trial
Pediatric Research · 2025-03 · 97 (3) · 1171-1182
DOI: 10.1038/s41390-024-03552-2 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Pediatric Research, online erschienen am 13.09.2024. Verfasst von He Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Graduate School of Fujian Medical University, Fuzhou, Fujian, China. Hauptthemen laut MEDLINE: Infant, Premature, Probiotics, Bifidobacterium, Gastrointestinal Microbiome. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Analyse the effects of Bifidobacterium BB-12 on intestinal metabolites and serum inflammatory factors in premature infants. METHODS: 71 premature infants at gestational age of ≤32 weeks were randomly divided into the probiotic (n = 36) and control (n = 35) groups. Faecal and blood samples were collected from the two groups of premature infants at the 2nd and 4th week of life for intestinal metabolite detection and assessment of the level of the serum inflammatory markers TLR4, NF- κ B, IL-1β, and TNF- α. RESULTS: Compared to the control group, the probiotic group contained more amino acids, these elements were enriched on multiple amino acid metabolic pathways, and the probiotic group showed significantly lower levels of the serum inflammatory markers TLR4, NF-κB, IL-1β, and TNF-α. Finally, the probiotic group showed a lower incidence of feeding intolerance. CONCLUSIONS: The administration of Bifidobacterium BB-12 is associated with increasing the levels of glutamine, glutamic acid, and kynurenine in the gut of premature infants, and associated with reducing the levels of TLR4 and NF-κB in the serum, further decreasing the secretion of the pro-inflammatory factors IL-1β and TNF-α, and alleviating systemic inflammatory reactions, thereby reducing the incidence of feeding intolerance. IMPACT: 1. The use of Bifidobacterium BB-12 in premature infants can increase the levels of amino acids in the intestine. 2. Increases in Bifidobacterium BB-12 may decrease the serum levels of TLR4, NF-κB, IL-1β, and TNF-α. 3. Kynurenine may improve the prognosis of preterm infants by reducing inflammation. 4. Bifidobacterium BB-12 may improve the feeding tolerance of premature infants, thus reducing the incidence of feeding intolerance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Graduate School of Fujian Medical University, Fuzhou, Fujian, China.
- Department of Neonatology, Quanzhou Maternity and Children's Hospital, Quanzhou, Fujian Province, China.
- The Graduate School of Fujian Medical University, Fuzhou, Fujian, China. lin3259627@163.com.
- Department of Neonatology, Quanzhou Maternity and Children's Hospital, Quanzhou, Fujian Province, China. lin3259627@163.com.
Zitieren
APA
Wang, H., Chen, D., Li, H., Fu, C., Fang, L., Wang, R., & Xu, J. (2025). Bifidobacterium regulates premature infant gut metabolites, reducing serum inflammatory factors: a randomised controlled trial. Pediatric Research, 97(3), 1171-1182. https://doi.org/10.1038/s41390-024-03552-2
Vancouver
Wang H, Chen D, Li H, Fu C, Fang L, Wang R, et al. Bifidobacterium regulates premature infant gut metabolites, reducing serum inflammatory factors: a randomised controlled trial. Pediatric Research. 2025;97(3):1171-1182. doi:10.1038/s41390-024-03552-2
BibTeX
@article{Wang2025,
author = {Wang, He and Chen, Dongmei and Li, Huamei and Fu, Chunyan and Fang, Lingyu and Wang, Ruiquan and Xu, Jinglin},
title = {Bifidobacterium regulates premature infant gut metabolites, reducing serum inflammatory factors: a randomised controlled trial},
journal = {Pediatric Research},
year = {2025},
volume = {97},
number = {3},
pages = {1171--1182},
doi = {10.1038/s41390-024-03552-2}
}
EUVIMED